Survival after chemotherapy and donor leukocyte infusions (DLIs) for patients with relapsed acute myelogenous leukemia (AML). Survival is significantly improved in recipients of DLI for relapsed AML more than 6 months after bone marrow transplantation (BMT; solid line) compared with recipients of DLI for relapse less than 6 months from BMT (dashed line; P < .001). Reprinted from Levine et al⁸⁸  with permission.